البحث | Bundas24

Rucha Pathak أضاف وظيفة جديدة أخرى
2025-06-02 06:14:56 -

Monoclonal Antibodies Market Companies: Growth, Share, Value, Analysis, and Trends
"Global Monoclonal Antibodies Market Size, Share, and Trends Analysis Report—Industry Overview and Forecast to 2032 Executive Summary: Global monoclonal antibodies market size was valued at USD 263.22 billion in 2024 and is projected to reach USD 719.81 billion by 2032, with a CAGR of 13.40% during the forecast period of 2025 to 2032. Monoclonal Antibodies...

0 التعليقات 0 المشاركات 155 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
Priti More أضاف وظيفة جديدة أخرى
2025-05-28 03:32:57 -

Monoclonal Antibodies Market Insights: Growth, Share, Value, Size, and Analysis
" Global Monoclonal Antibodies Market Size, Share, and Trends Analysis Report—Industry Overview and Forecast to 2032 Executive Summary: Global monoclonal antibodies market size was valued at USD 263.22 billion in 2024 and is projected to reach USD 719.81 billion by 2032, with a CAGR of 13.40% during the forecast period of 2025 to 2032. Global Monoclonal Antibodies...

0 التعليقات 0 المشاركات 175 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
Rucha Pathak أضاف وظيفة جديدة أخرى
2025-06-04 08:18:59 -

Monoclonal Antibodies Market Opportunities, Industry Statistics, Trends, Revenue Analysis
"Executive Summary: Global monoclonal antibodies market size was valued at USD 263.22 billion in 2024 and is projected to reach USD 719.81 billion by 2032, with a CAGR of 13.40% during the forecast period of 2025 to 2032. The Monoclonal Antibodies Market is experiencing unprecedented growth driven by rapid technological advancements, evolving consumer preferences, and...

0 التعليقات 0 المشاركات 105 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!
Kajalpatil Patil أضاف وظيفة جديدة Health
2025-05-22 08:51:56 -

PCSK9 Inhibitors Market Driven by Cardiovascular Disease Prevalence
PCSK9 inhibitors are a class of lipid-lowering biologics designed to target proprotein convertase subtilisin/kexin type 9, offering a potent reduction in low-density lipoprotein (LDL) cholesterol for patients at high cardiovascular risk. Administered via subcutaneous injection, these monoclonal antibodies and small molecules block PCSK9 interaction with LDL receptors, enhancing receptor...

0 التعليقات 0 المشاركات 230 مشاهدة 0 معاينة

الرجاء تسجيل الدخول , للأعجاب والمشاركة والتعليق على هذا!